Vaxil Bio Ltd.
VXL.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 48.80K | 21.40K | 39.60K | 45.30K | 28.20K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 51.60K | 22.90K | 41.80K | 35.80K | 43.00K |
| Operating Income | -51.60K | -22.90K | -41.80K | -35.80K | -43.00K |
| Income Before Tax | -48.80K | -15.70K | -35.90K | -35.80K | -43.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -48.80K | -15.70K | -35.90K | -35.80K | -43.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -48.80K | -15.70K | -35.90K | -35.80K | -43.00K |
| EBIT | -51.60K | -22.90K | -41.80K | -35.80K | -43.00K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.02 | -0.01 | -0.01 | -0.01 | -0.02 |
| Normalized Basic EPS | -0.01 | 0.00 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.02 | -0.01 | -0.01 | -0.01 | -0.02 |
| Normalized Diluted EPS | -0.01 | 0.00 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 2.74M | 2.74M | 2.74M | 2.74M | 2.74M |
| Average Diluted Shares Outstanding | 2.74M | 2.74M | 2.74M | 2.74M | 2.74M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |